Literature DB >> 6292291

Immune deficiency in the X-linked lymphoproliferative syndrome. II. Immunoregulatory T cell defects.

T Lindsten, J K Seeley, M Ballow, K Sakamoto, S St Onge, J Yetz, P Aman, D T Purtilo.   

Abstract

Surface phenotypic markers and the function of lymphocytes in patients affected with the X-linked lymphoproliferative syndrome (XLP) were studied. This syndrome is characterized by a defective response to infection with Epstein Barr virus (EBV). Normal numbers of B and T cells were detected with anti-Ig and monoclonal OKT3 antisera, respectively. T cell subset values, however, were persistently altered: cells reacting with OKT8 were significantly elevated in five of nine patients, accompanied by a slight decrease in the percentage of OKT4-positive cells, leading to abnormally low OKT4 to OKT8 ratios. One patient had a high OKT4 to OKT8 ratio due to low number of OKT8-positive cells. Lymphocytes from patients showed normal proliferation after stimulation with T and B cell mitogens. In contrast, Ig synthesis by lymphocytes after stimulation with B cell mitogens was markedly deficient: low or undetectable levels of one or all classes of Ig were detected, whereas cell lines established from EBV-infected B lymphocytes from patients produced normal quantities of Ig. These studies imply immune regulatory impairments in the patient with XLP.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292291

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Immunological reason for chronic ill health after infectious mononucleosis.

Authors:  T J Hamblin; J Hussain; A N Akbar; Y C Tang; J L Smith; D B Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-09

3.  Varicella pneumonia in a bone marrow-transplanted, immune-reconstituted adenosine deaminase-deficient patient with severe combined immunodeficiency disease.

Authors:  M Ballow; R Hirschhorn
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

4.  Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity.

Authors:  F Rousset; G Souillet; M G Roncarolo; J P Lamelin
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

5.  Selective generation of functional somatically mutated IgM+CD27+, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease.

Authors:  Cindy S Ma; Stefania Pittaluga; Danielle T Avery; Nathan J Hare; Irina Maric; Amy D Klion; Kim E Nichols; Stuart G Tangye
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

6.  Sporadic postinfectious neuromyasthenia.

Authors:  I E Salit
Journal:  CMAJ       Date:  1985-10-01       Impact factor: 8.262

7.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

8.  T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.

Authors:  Lihi Radomir; Sivan Cohen; Matthias P Kramer; Eszter Bakos; Hadas Lewinsky; Avital Barak; Ziv Porat; Richard Bucala; Polina Stepensky; Shirly Becker-Herman; Idit Shachar
Journal:  J Immunol       Date:  2017-09-13       Impact factor: 5.422

Review 9.  XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP.

Authors:  Stuart G Tangye
Journal:  J Clin Immunol       Date:  2014-08-02       Impact factor: 8.317

10.  Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.

Authors:  C Tsoukas; F Gervais; A Fuks; R D Guttmann; H Strawczynski; J Shuster; P Gold
Journal:  Can Med Assoc J       Date:  1983-10-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.